ABBV AbbVie Stock Outlook 2026: Skyrizi and Rinvoq Prove the Humira Replacement Was Real
AbbVie (ABBV) stock outlook 2026. Humira biosimilar erosion absorbed, Skyrizi+Rinvoq now exceeding peak Humira combined, 3.41% dividend yield, 12-month price target scenarios analyzed.
ABBV AbbVie dividend aristocrat